Pan American League of Associations for Rheumatology Guidelines for the Treatment of Takayasu Arteritis
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved..
OBJECTIVE: To develop the first evidence-based Pan American League of Associations for Rheumatology (PANLAR) guidelines for the treatment of Takayasu arteritis (TAK).
METHODS: A panel of vasculitis experts developed a series of clinically meaningful questions addressing the treatment of TAK patients in the PICO (population/intervention/comparator/outcome) format. A systematic literature review was performed by a team of methodologists. The evidence quality was assessed according to the GRADE (Grading of Recommendations/Assessment/Development/Evaluation) methodology. The panel of vasculitis experts voted each PICO question and made recommendations, which required ≥70% agreement among the voting members.
RESULTS: Eleven recommendations were developed. Oral glucocorticoids are conditionally recommended for newly diagnosed and relapsing TAK patients. The addition of nontargeted synthetic immunosuppressants (e.g., methotrexate, leflunomide, azathioprine, or mycophenolate mofetil) is recommended for patients with newly diagnosed or relapsing disease that is not organ- or life-threatening. For organ- or life-threatening disease, we conditionally recommend tumor necrosis factor inhibitors (e.g., infliximab or adalimumab) or tocilizumab with consideration for short courses of cyclophosphamide as an alternative in case of restricted access to biologics. For patients relapsing despite nontargeted synthetic immunosuppressants, we conditionally recommend to switch from one nontargeted synthetic immunosuppressant to another or to add tumor necrosis factor inhibitors or tocilizumab. We conditionally recommend low-dose aspirin for patients with involvement of cranial or coronary arteries to prevent ischemic complications. We strongly recommend performing surgical vascular interventions during periods of remission whenever possible.
CONCLUSION: The first PANLAR treatment guidelines for TAK provide evidence-based guidance for the treatment of TAK patients in Latin American countries.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases - 29(2023), 7 vom: 01. Okt., Seite 316-325 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Souza, Alexandre Wagner S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunosuppressive Agents |
|---|
| Anmerkungen: |
Date Completed 27.09.2023 Date Revised 27.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/RHU.0000000000002004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360535011 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360535011 | ||
| 003 | DE-627 | ||
| 005 | 20231226083222.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/RHU.0000000000002004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360535011 | ||
| 035 | |a (NLM)37553869 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Souza, Alexandre Wagner S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pan American League of Associations for Rheumatology Guidelines for the Treatment of Takayasu Arteritis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2023 | ||
| 500 | |a Date Revised 27.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: To develop the first evidence-based Pan American League of Associations for Rheumatology (PANLAR) guidelines for the treatment of Takayasu arteritis (TAK) | ||
| 520 | |a METHODS: A panel of vasculitis experts developed a series of clinically meaningful questions addressing the treatment of TAK patients in the PICO (population/intervention/comparator/outcome) format. A systematic literature review was performed by a team of methodologists. The evidence quality was assessed according to the GRADE (Grading of Recommendations/Assessment/Development/Evaluation) methodology. The panel of vasculitis experts voted each PICO question and made recommendations, which required ≥70% agreement among the voting members | ||
| 520 | |a RESULTS: Eleven recommendations were developed. Oral glucocorticoids are conditionally recommended for newly diagnosed and relapsing TAK patients. The addition of nontargeted synthetic immunosuppressants (e.g., methotrexate, leflunomide, azathioprine, or mycophenolate mofetil) is recommended for patients with newly diagnosed or relapsing disease that is not organ- or life-threatening. For organ- or life-threatening disease, we conditionally recommend tumor necrosis factor inhibitors (e.g., infliximab or adalimumab) or tocilizumab with consideration for short courses of cyclophosphamide as an alternative in case of restricted access to biologics. For patients relapsing despite nontargeted synthetic immunosuppressants, we conditionally recommend to switch from one nontargeted synthetic immunosuppressant to another or to add tumor necrosis factor inhibitors or tocilizumab. We conditionally recommend low-dose aspirin for patients with involvement of cranial or coronary arteries to prevent ischemic complications. We strongly recommend performing surgical vascular interventions during periods of remission whenever possible | ||
| 520 | |a CONCLUSION: The first PANLAR treatment guidelines for TAK provide evidence-based guidance for the treatment of TAK patients in Latin American countries | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 700 | 1 | |a Sato, Emilia I |e verfasserin |4 aut | |
| 700 | 1 | |a Brance, Maria Lorena |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Ávila, Daniel G |e verfasserin |4 aut | |
| 700 | 1 | |a Scolnik, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Magri, Sebastián Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Ugarte-Gil, Manuel Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Flores-Suárez, Luis Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Saldarriaga-Rivera, Lina María |e verfasserin |4 aut | |
| 700 | 1 | |a Babini, Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Zamora, Natalia V |e verfasserin |4 aut | |
| 700 | 1 | |a Acosta Felquer, María Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Vergara, Facundo |e verfasserin |4 aut | |
| 700 | 1 | |a Carlevaris, Leandro |e verfasserin |4 aut | |
| 700 | 1 | |a Scarafia, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano Guppy, Enrique Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Unizony, Sebastian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases |d 1995 |g 29(2023), 7 vom: 01. Okt., Seite 316-325 |w (DE-627)NLM094595941 |x 1536-7355 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:7 |g day:01 |g month:10 |g pages:316-325 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/RHU.0000000000002004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 7 |b 01 |c 10 |h 316-325 | ||